Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
J.Molner ASOTSE:MOLNR -0.53%40 Gross Margin % is 35.46% as of Dec. 2025, which is 52% below its 10-year median of 73.27. GuruFocus rates OTSE:MOLNR with a GF Score™ of 40/100 and a GF Value™ of €19.62 (Fairly Valued). The stock has 7 warning signs investors should review. Among 939 Drug Manufacturers companies, J.Molner AS ranks better than 71.67% on this metric.
The historical rank and industry rank for J.Molner AS's Gross Margin % or its related term are showing as below:
OTSE:MOLNR'
s Gross Margin % Range Over the Past 10 Years
Min: 42.66 Med: 73.27 Max: 155.5
Current: 61.52
During the past 5 years, the highestGross Margin % of J.Molner AS was 155.50%. The lowest was 42.66%. And the median was 73.27%.
OTSE:MOLNR's Gross Margin % is ranked better than 71.67% of 939
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs OTSE:MOLNR: 61.52
J.Molner AS had a gross margin of 35.46% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for J.Molner AS was 0.00% per year.
J.Molner AS (OTSE:MOLNR) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
J.Molner AS had a gross margin of 35.46% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
J.Molner AS Gross Margin % Related Terms
J.Molner AS Gross Margin % Historical Data
* Premium members only.
The historical data trend for J.Molner AS's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTSE:MOLNR vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J.Molner AS Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's Gross Margin % distribution charts can be found below:
* The bar in red indicates where J.Molner AS's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
J.Molner AS (OTSE:MOLNR) has a Gross Margin % of 35.46% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on J.Molner AS and its competitors. This is 52% below median its historical median of 73.27. Over the past decade, J.Molner AS's Gross Margin % has ranged from 42.66 to 155.50. According to the industry distribution chart, J.Molner AS ranks #266 out of 939 companies in the Drug Manufacturers industry, placing it in the top 28.3%.
Is J.Molner AS's Gross Margin % too high?
J.Molner AS's current Gross Margin % of 35.46% is 52% below median its 10-year median of 73.27. Over the past 10 years, this metric has ranged from a low of 42.66 to a high of 155.50. The Drug Manufacturers industry median Gross Margin % is 48.54. J.Molner AS's value of 35.46% is 26.9% below this industry median. Based on the distribution chart, J.Molner AS ranks #266 out of 939 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, J.Molner AS ranks #266 out of 939 companies for Gross Margin %. This puts J.Molner AS in the upper half of its industry. The industry median Gross Margin % is 48.54. J.Molner AS's value of 35.46% is 26.9% below this benchmark. Historically, J.Molner AS's own Gross Margin % has ranged from 42.66 to 155.50 over the past decade. While the company's 10-year median is 73.27 vs. the industry median of 48.54, J.Molner AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. J.Molner AS's current Gross Margin % of 35.46% is 26.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on J.Molner AS and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J.Molner AS's current Gross Margin % is 35.46%, which is 52% below median its own 10-year median of 73.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.62, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current Gross Margin % is 35.46%, which is 52% below median its 10-year median of 73.27 and 26.9% below the Drug Manufacturers industry median of 48.54. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current Gross Margin % is 35.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62.
GuruFocus considers J.Molner AS to be Fairly Valued.
Key valuation signals for OTSE:MOLNR:
Gross Margin %: 35.46% (52% below median its 10-year median of 73.27)
GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
Industry Position: 26.9% below the Drug Manufacturers median (#266 of 939)
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score
Get the complete analysis for OTSE:MOLNR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
